Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SB756050
- Development stage
- Phase 1
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SB756050 is a selective small molecule agonist of the bile acid receptor TGR5 (also known as GPBAR1). It was developed primarily for the potential treatment of type 2 diabetes mellitus by modulating glucose metabolism through activation of TGR5, which influences insulin secretion and glucose disposal. The drug exhibits nonlinear pharmacokinetics with less than dose-proportional increases in plasma exposure above 100 mg and shows variable pharmacodynamic effects on glucose levels depending on dose. It has been studied in phase 1 and phase 2 clinical trials but development for type 2 diabetes was discontinued. SB756050 was originally developed by GlaxoSmithKline.
- Other names
- SB-756050SB756050SB 756050
02
Targets
GPBAR1
Beyond the preview
Go deeper on SB756050.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SB756050.